LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPH
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and OB on Behalf of Shareholders
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. - LBPH
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump
S&P 500 hits record high; Dow gains as Longboard Pharmaceuticals surges 51% and tech stocks rise
Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 billion deal to acquire the company
Longboard Pharmaceutical Stock Soars 51%. It's Being Bought for $2.6 Billion.
LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders
Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussion of Topline Phase 1 SAD Data
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
Longboard Stock Soars on FDA Designations for Epilepsy Drug
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
Top 3 Health Care Stocks That May Crash This Quarter
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
This biotech stock has surged over 300% this week
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today?
Longboard Pharmaceuticals stock soars on seizure drug results
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)